Skip to main content
SpringerLink
Log in

Amyloid-β PET Imaging in Aging and Dementia

  • Chapter
  • First Online:
PET/CT in Brain Disorders

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

  • 916 Accesses

Abstract

Amyloid-β imaging with positron emission tomography (PET) has been around since the early 2000s. It has transformed neuroimaging in Alzheimer’s disease (AD) by facilitating in vivo detection (and quantification) of amyloid-β plaques, one of the core pathological features of AD [1]. Initially, it was primarily used for research purposes and only infrequently in clinical practice. Now, more than a decade after the initial publications, it has become a standard diagnostic aid in specialised memory clinics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12(10):383–8.

    Article  CAS  PubMed  Google Scholar 

  2. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.

    Article  CAS  PubMed  Google Scholar 

  3. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131(Pt 6):1630–45.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bergeron D, Ossenkoppele R Jr, Laforce R. Evidence-based interpretation of amyloid-beta PET results: a clinician’s tool. Alzheimer Dis Assoc Disord. 2018;32(1):28–34.

    Article  PubMed  Google Scholar 

  5. Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79(3):229–36.

    Article  PubMed  CAS  Google Scholar 

  6. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol. 2008;63(3):377–87.

    Article  CAS  PubMed  Google Scholar 

  7. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275–83.

    Article  PubMed  Google Scholar 

  8. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29.

    Article  PubMed  Google Scholar 

  10. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.

    Article  CAS  PubMed  Google Scholar 

  11. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54(1):70–7.

    Article  CAS  PubMed  Google Scholar 

  12. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923–6.

    Article  PubMed  Google Scholar 

  13. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9.

    Article  CAS  PubMed  Google Scholar 

  14. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):16.

    Article  Google Scholar 

  15. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94.

    Article  CAS  PubMed  Google Scholar 

  16. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24(5):375–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer’s disease. Brain. 2007;130(Pt 10):2636–45.

    Article  CAS  PubMed  Google Scholar 

  21. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–49.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1–4.

    Article  PubMed  Google Scholar 

  23. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–52.

    Article  CAS  PubMed  Google Scholar 

  24. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205–12.

    Article  CAS  PubMed  Google Scholar 

  26. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–25.

    Article  CAS  PubMed  Google Scholar 

  27. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ballard C, Ziabreva I, Perry R, Larsen JP, O’Brien J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67(11):1931–4.

    Article  CAS  PubMed  Google Scholar 

  29. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026–36.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.

    Article  CAS  PubMed  Google Scholar 

  32. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135.(Pt 7:2126–39.

    Article  PubMed  Google Scholar 

  33. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800.

    Article  PubMed  Google Scholar 

  34. Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W, et al. Asymmetries of amyloid-beta burden and neuronal dysfunction are positively correlated in Alzheimer’s disease. Brain. 2015;138(Pt 10):3089–99.

    Article  PubMed  Google Scholar 

  35. Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, et al. Amyloid burden and metabolic function in early-onset Alzheimer’s disease: parietal lobe involvement. Brain. 2012;135(Pt 7):2115–25.

    Article  PubMed  Google Scholar 

  36. Martersteck A, Murphy C, Rademaker A, Wieneke C, Weintraub S, Chen K, et al. Is in vivo amyloid distribution asymmetric in primary progressive aphasia? Ann Neurol. 2016;79(3):496–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):4.

    Article  Google Scholar 

  39. Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414–21.

    Article  PubMed  Google Scholar 

  40. Grundman M, Johnson KA, Lu M, Siderowf A, Dell’Agnello G, Arora AK, et al. Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: impact of appropriate use criteria. Dement Geriatr Cogn Disord. 2016;41(1–2):80–92.

    Article  CAS  PubMed  Google Scholar 

  41. Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58(11):1711–7.

    Article  PubMed  Google Scholar 

  42. Ben Bouallegue F, Mariano-Goulart D, Payoux P, Alzheimer’s Disease Neuroimaging Initiative (ADNI). Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther. 2017;9(1):32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer’s disease. Brain. 2015;138(Pt 3):772–83.

    Article  PubMed  Google Scholar 

  44. Hornberger J, Michalopoulos S, Dai M, Andrade P, Dilla T, Happich M. Cost-effectiveness of florbetapir-PET in Alzheimer’s disease: a Spanish Societal perspective. J Ment Health Policy Econ. 2015;18(2):63–73.

    PubMed  Google Scholar 

  45. Hornberger J, Bae J, Watson I, Johnston J, Happich M. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer’s disease - the case of florbetapir. Curr Med Res Opin. 2017;33(4):675–85.

    Article  CAS  PubMed  Google Scholar 

  46. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087–95.

    Article  CAS  PubMed  Google Scholar 

  47. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13(3):205–16.

    Article  PubMed  Google Scholar 

  49. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):4.

    Article  Google Scholar 

  50. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med. 2009;50(3):348–55.

    Article  CAS  PubMed  Google Scholar 

  51. van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imaging Division, Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands

    Nelleke Tolboom

  2. Alzheimer Center, Amsterdam University Medical Center, Amsterdam, The Netherlands

    Rik Ossenkoppele

  3. Clinical Memory Research Unit, Lund University, Lund, Sweden

    Rik Ossenkoppele

  4. Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands

    Bart N. van Berckel

Authors
  1. Nelleke Tolboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rik Ossenkoppele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bart N. van Berckel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nelleke Tolboom .

Editor information

Editors and Affiliations

  1. Institute of Nuclear Medicine, University College London, London, UK

    Francesco Fraioli

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tolboom, N., Ossenkoppele, R., van Berckel, B.N. (2019). Amyloid-β PET Imaging in Aging and Dementia. In: Fraioli, F. (eds) PET/CT in Brain Disorders. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-030-01523-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-01523-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-01522-0

  • Online ISBN: 978-3-030-01523-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation